Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry

被引:15
|
作者
Matsuo, Ryu [1 ,2 ]
Kamouchi, Masahiro [2 ,3 ]
Fukuda, Haruhisa [2 ,3 ]
Hata, Jun [1 ,3 ]
Wakisaka, Yoshinobu [1 ]
Kuroda, Junya [1 ]
Ago, Tetsuro [1 ]
Kitazono, Takanari [1 ,3 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka 812, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka 812, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Fukuoka 812, Japan
来源
PLOS ONE | 2014年 / 9卷 / 10期
关键词
RT-PA; TRIAL IST-3; MANAGEMENT; GREATER-THAN-OR-EQUAL-TO-80; ALTEPLASE; TPA;
D O I
10.1371/journal.pone.0110444
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: Of 13,521 stroke patients registered in the Fukuoka Stroke Registry in Japan from June 1999 to February 2013, 953 ischemic stroke patients who were over 80 years old, hospitalized within 3 h of onset, and not treated with endovascular therapy were included in this study. Among them, 153 patients were treated with intravenous rt-PA (0.6 mg/kg). For propensity score (PS)-matched case-control analysis, 148 patients treated with rt-PA and 148 PS-matched patients without rt-PA therapy were selected by 1:1 matching with propensity for using rt-PA. Clinical outcomes were neurological improvement, good functional outcome at discharge, in-hospital mortality, and hemorrhagic complications (any intracranial hemorrhage [ICH], symptomatic ICH, and gastrointestinal bleeding). Results: In the full cohort of 953 patients, rt-PA use was associated positively with neurological improvement and good functional outcome, and negatively with in-hospital mortality after adjustment for multiple confounding factors. In PS-matched case-control analysis, patients treated with rt-PA were still at lower risk for unfavorable clinical outcomes than non-treated patients (neurological improvement, odds ratio 2.67, 95% confidence interval 1.61-4.40; good functional outcome, odds ratio 2.23, 95% confidence interval 1.16-4.29; in-hospital mortality, odds ratio 0.30, 95% confidence interval 0.13-0.65). There was no significant association between rt-PA use and risk of hemorrhagic complications in the full and PS-matched cohorts. Conclusions: Intravenous rt-PA therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged. 80 years) with acute ischemic stroke.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry
    Matsuo, Ryu
    Kamouchi, Masahiro
    Ago, Tetsuro
    Hata, Jun
    Shono, Yuji
    Kuroda, Junya
    Wakisaka, Yoshinobu
    Sugimori, Hiroshi
    Kitazono, Takanari
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2014, 14 (04) : 954 - 959
  • [2] Outcome of intravenous recombinant tissue plasminogen activator for acute ischemic stroke in patients aged over 80 years
    Mione, Gioia
    Ducrocq, Xavier
    Thilly, Nathalie
    Lacour, Jean-Christophe
    Vespignani, Herve
    Richard, Sebastien
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2016, 16 (07) : 843 - 849
  • [3] Intravenous Thrombolysis with Recombinant Tissue-type Plasminogen Activator for Acute Ischemic Stroke in Patients with Metabolic Syndrome
    Sobolewski, Piotr
    Brola, Waldemar
    Szczuchniak, Wiktor
    Fudala, Magorzata
    Kozera, Grzegorz
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (08) : 1787 - 1792
  • [4] Safety and effectiveness of intravenous thrombolysis with recombinant tissue plasminogen activator in eighty years and older acute ischemic stroke patients
    Chen, Y.
    Li, C. -H.
    Wang, Y. -X.
    Zhang, C. -H.
    Dong, Z.
    Zhang, F. -F.
    Wang, J. -H.
    Zhang, P. -L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (10) : 1852 - 1858
  • [5] Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban
    van Hooff, Robbert-Jan
    Nieboer, Koenraad
    De Smedt, Ann
    Yperzeele, Laetitia
    Jochmans, Kristin
    De Keyser, Jacques
    Brouns, Raf
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 122 : 133 - 134
  • [6] Systemic thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: first Croatian experiences
    Matijevic, Vesna
    Alvir, Domagoj
    Malojcic, Branko
    Unusic, Lea
    Supe, Svjetlana
    Boban, Marina
    Bujan-Kovac, Andrea
    Habek, Mario
    Poljakovic, Zdravka
    NEUROLOGICAL SCIENCES, 2010, 31 (06) : 693 - 697
  • [7] Update on Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
    Fugate, Jennifer E.
    Rabinstein, Alejandro A.
    MAYO CLINIC PROCEEDINGS, 2014, 89 (07) : 960 - 972
  • [8] Intravenous Thrombolysis With Low-Dose Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Response
    Toyoda, Kazunori
    Koga, Masatoshi
    Minematsu, Kazuo
    STROKE, 2010, 41 (03) : E165 - E165
  • [9] Effect of standardized nursing cooperation on intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke
    Yin, Chunhong
    Qi, Li
    Jing, Xia
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (10): : 11925 - 11931
  • [10] Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry
    Kobayashi, A.
    Czlonkowska, A.
    Ahmed, N.
    Romanowicz, S.
    Glonek, M.
    Nyka, W. M.
    Opala, G.
    Wahlgren, N.
    ACTA NEUROLOGICA SCANDINAVICA, 2010, 122 (04): : 229 - 236